Respiri’s innovative devices and apps use digital wheeze detection and measurement technology, replacing outdated and difficult-to-use instruments for lung function testing such as peak flow meters.
Respiri’s clinically proven patented technology is used in major hospitals in UK, Europe, USA, Japan, Korea and Australia.
Respiri operates in an industry subset of the globally attractive health and technology sectors and is well positioned as one of the few companies in the world producing the next wave of consumer focused technology for complex disease management.
Our unique proprietary Acoustic Respiratory Monitoring (ARM™) technology records airway sounds to detect continuous adventitious breath sounds (CABS) and measure the extent of wheezing caused by airway obstruction.
Respiri devices work like a stethoscope, utilizing contact sensors to acquire breath sounds at the windpipe (trachea).
An Australian owned medical device company first listed on the ASX in 2006, Respiri Limited (ASH:RSH) recently changed its name from iSonea Limited (ASX:ISN) to reflect a fundamental business transformation and its focus on respiratory health.
